DiaMedica Therapeutics Inc. DMAC
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
4.19
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$32.8M | — | -$29.1M | $56.1M |
| 2024 | — | -$24.4M | — | -$22.1M | $40.7M |
| 2023 | — | -$19.4M | — | -$18.8M | $51.1M |
| 2022 | — | -$13.7M | — | -$11.6M | $31.8M |
| 2021 | — | -$13.6M | — | -$12.3M | $44.0M |
| 2020 | — | -$12.3M | — | -$9.2M | $26.0M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.19 (safe)
- Working capital / assets 0.904
- Retained earnings / assets -2.815
- EBIT / assets -0.56
- Equity / liabilities 10.667
Source: SEC EDGAR filings · CIK 0001401040 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.